1. Healthcare resource utilisation and suicidal ideation amongst adolescents in the US with posttraumatic stress disorder, major depressive disorder, and substance use disorders using electronic health records.
- Author
-
Chan KMY, Low LT, Wong JG, Kuah S, and Rush AJ
- Subjects
- Humans, Adolescent, Female, Male, United States epidemiology, Child, Emergency Service, Hospital statistics & numerical data, Patient Acceptance of Health Care statistics & numerical data, Hospitalization statistics & numerical data, Cohort Studies, Health Resources statistics & numerical data, Stress Disorders, Post-Traumatic epidemiology, Suicidal Ideation, Depressive Disorder, Major epidemiology, Electronic Health Records statistics & numerical data, Substance-Related Disorders epidemiology, Comorbidity
- Abstract
Background: While PTSD is commonly associated with multiple comorbidities, studies have yet to quantify the impact of these comorbidities on key clinical outcomes and HCRU. This study explored risks of emergency room (ER) visits, inpatient admissions (IA), suicidal ideation (SI), and treatment follow-up duration (FU), amongst PTSD patients with comorbid MDD and/or SUD., Methods: Using real-world data (RWD) generated by electronic health records accessed from the NeuroBlu database, a cohort of adolescent patients (12-17 yrs) was examined over a one-year study period following PTSD diagnosis., Results: 5794 patients were included in the cohort. Compared to patients with only PTSD (n = 3061), those with comorbid MDD (n = 1820) had greater odds of ER (4.5 times), IA (1.6 times), and FU (4.3 times). Those with comorbid SUD (n = 653) had greater odds of IA (4.5 times), shorter FU (34 days), and lower odds of ER (0.5 times). Both comorbidities (n = 260) had greater odds of ER (3.8 times), IA (2.6 times), SI (3.6 times), and shorter FU (12 days)., Limitations: These RWD had a high proportion of missingness. Health records of patients who changed service providers could not be accounted for in this study., Conclusions: Both MDD and SUD substantially elevated the risk of HCRU and suicidal ideation for PTSD patients., Competing Interests: Declaration of competing interest A. John Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson and Johnson (Janssen), Liva-Nova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US;speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co- inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors:McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Kelly Chan, Li Tong Low, Joshua Wong, and Sherwin Kuah are employees of Holmusk Technologies, Inc. when the research was undertaken., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF